Genetic modelling of the estrogen metabolism as a risk factor of hormone-dependent disorders

Maturitas

Volumn 42, Issue 1, 2002, Pages 1-12

  Huber, J C ^a   Schneeberger, C ^a   Tempfer, C B ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Catechol O methyltransferase; Estrogen; Parkinson's disease; Polycystic ovary syndrome

Indexed keywords

AROMATASE; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; CYTOCHROME P450C17; ESTRADIOL;

BREAST CARCINOMA; CANCER RISK; CANCER SUSCEPTIBILITY; DISEASE PREDISPOSITION; ENDOMETRIUM CARCINOMA; ESTROGEN METABOLISM; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYDROXYLATION; LUNG CARCINOMA; OVARY POLYCYSTIC DISEASE; PARKINSON DISEASE; PROSTATE CARCINOMA; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE;

ARYL HYDROCARBON HYDROXYLASES; CATECHOL O-METHYLTRANSFERASE; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 ENZYME SYSTEM; ESTRADIOL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MODELS, GENETIC; NEOPLASMS, HORMONE-DEPENDENT; NERVOUS SYSTEM DISEASES; POLYCYSTIC OVARY SYNDROME; RISK FACTORS; STEROID 17-ALPHA-HYDROXYLASE;

EID: 0037140675     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(02)00021-X     Document Type: Review

References (94)

1. Estrogen receptor pathways to AP-1
2. Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders
3. Catecholoestrogens (2-and 4-hydroxyoestrogens): Chemistry, biogenesis, metabolism, occurrence and physiological significance
4. P 450 enzymes of estrogen metabolism
5. Molecular mechanisms of estrogen carcinogenesis
6. Molecular origin of cancer-catechol estrogen-3,4-quinones as endogenous tumor initiators
7. Biogenesis and inactivation of catecholestrogens
8. Global variation in the frequencies of functionally different catechol-O-methyltransferase alleles
9. High and low activity alleles of catechol-O-methyltransferase gene: Ethnic difference and possible association with Parkinson's disease
10. Methylation pharmacogenetics: Catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase
11. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP 17, CYP 1A1, and COMT: A multigene study on cancer susceptibility
12. Progression of human breast cancers to the metastatic state is linked to genotypes of catechol-O-methyltransferase
13. Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer risk
14. An association between allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer
15. Polymorphic catechol-O-methyltransferase gene and breast cancer risk
16. Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease
17. Effect of COMT Val108/158Met genotype on frontal lobe function and risk for schizophrenia
18. Catechol-O-methyltransferase activity: A determinant of levodopa response
19. The COMT allele modifies the association between MAOB polymorphism and PD in Taiwanese
20. Catechol-O-methyltransferase genotype and susceptibility to Parkinson's disease in Japan
21. Variability and validity of polymorphism association studies in Parkinson's disease
22. Association between the functional polymorphism of catechol-O-methyltransferase gene and alcohol consumption among social drinkers
23. Suicidal behavior in patients with schizophrenia is related to COMT polymorphism
24. Significance of the catechol-O-methyltransferase gene polymorphism in migraine
25. Association of anorexia nervosa with the high activity allele of the COMT gene: A family-based study in Israeli patients
26. Linkage study of catechol-O-methyltransferase and attention-deficit hyperactivity disorder
27. An association study between 5-HTTLPR polymorphism, COMT polymorphism, and Tourette's syndrome
28. Cytochromes P450 in the rat and man: Methods of investigation, substrate specificities, and relevance to cancer
29. CYP 1A1 polymorphism and risk of lung cancer in relation to tobacco smoking: A case-control study in China
30. Cytochrome P4501A1 polymorphisms in South American Indians
31. CYP1A1 polymorphisms and lung cancer risk: A meta-analysis
32. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier to tobacco-related cancers
33. Gender differences in genetic susceptibility for lung cancer
34. Parental smoking, CYP1A1 genetic polymorphisms, and childhood leukemia
35. Differential expression of oncogenes c-fos, c-myc, and Her-2/neu induced by estradiol and 16 alpha hydroxyestrone in human breast cancer cell line and the progesterone receptor
36. Regulation of growth factors by estrogen through the estrogen receptor
37. Indolo[3,2-b] carbazole: A dietary derived factor that exhibits both antiestrogenic and estrogenic activity
38. Effect of transient expression of the estrogen receptor on constitutive and inducible CYP1A1 in Hs578T human breast cancer cells
39. Role of estradiol metabolism and CYP1A1 polymorphism in breast cancer risk
40. Molecular epidemiology of breast cancer: Genetic variation in steroid hormone metabolism
41. Cigarette smoking, cytochrome P4501A1 polymorphisms, and breast cancer risk in the Nurses' Health Study
42. Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP 1A2, CYP2E1, glutathione S-transferase (GST) M1, and GSTT1 and susceptibility to prostate cancer in the Japanese population
43. Genetic polymorphism of enzymes involved in xenobiotic metabolism and the risk of colorectal cancer
44. Genetically high susceptibility to oral squamous cell carcinoma in terms of combined genotyping of CYP1A1 and GSTM1 genes
45. Endometriosis in rhesus monkeys (Macaca mulatta) following chronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin
46. Dioxin pollution and endometriosis in Belgium
47. Dioxin concentrations in women with endometriosis
48. Regulation of cytochrome P-450 (CYP) 1B1 in mouse Hepa-1 variant cell lines: A possible role for aryl hydrocarbon receptor nuclear translocator (ARNT) as a suppressor of CYP1B1 gene expression
49. Expression of dioxin-related transactivating factors and target genes in human eutopic endometrial and endometriotic tissues
50. 17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1
51. Oxidation of xenobiotics by recombinant human cytochrome P450 1B1
52. Human CYP1B1 and anticancer agent metabolism: Mechanism for tumor-specific drug inactivation?
53. Molecular genetics of primary congenital glaucoma
54. Human CYP1B1 Leu432Val gene polymorphism: Ethnic distribution in African-Americans, Caucasians, and Chinese; Estradiol hydroxylase activity; And distribution in prostate cancer cases and controls
55. Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism
56. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer
57. Genetic polymorphism of cytochrome P450-1B1 and risk of breast cancer
58. Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer
59. Mutations in CYP1B1, the gene for cytochrome P4501B1, are the predominant cause of primary congenital glaucoma in Saudi Arabia
60. Identification of a single ancestral CYP1B1 mutation in Slovak Gypsies (Roms) affected with primary congenital glaucoma
61. A novel truncating mutation of cytochrome P4501B1 (CYP1B1) gene in primary infantile glaucoma
62. Cloning and sequence of the human gene for p450c17 [steroid 17 alpha-hydroxylase/17,20 lyase]: Similarity with the gene for P450c21
63. Cytochrome p450c 17 alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations
64. Cytochrome P450c17alpha gene (CYP 17) polymorphism predicts use of hormone replacement therapy
65. A polymorphism in the CYP 17 gene increases the risk of breast cancer
66. Association between CYP17 gene polymorphism and risk of breast cancer in young women
67. CYP17 genotype and breast cancer risk
68. Association between CYP17 polymorphisms and the development of breast cancer
69. CYP17 polymorphism in the groups of distinct breast cancer susceptibility: Comparison of patients with bilateral disease vs. monolateral breast cancer patients vs. middle-aged female controls vs. elderly tumor-free women
70. No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer
71. No association of the 5′ promoter polymorphism of CYP17 with breast cancer risk in Japan
72. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer
73. Steroid metabolism gene CYP17 polymorphism and the development of breast cancer
74. CYP17 promoter polymorphism and ovarian cancer risk
75. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17
76. Polymorphism T-C (-34 bp) of gene CYP17 promoter in Greek patients with polycystic ovary syndrome
77. A polymorphism in the CYP17 gene is associated with male breast cancer
78. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2)
79. A polymorphism in the CYP17 gene is associated with prostate cancer risk
80. Structural analysis of the gene encoding human aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis
81. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk
82. Aromatase activity in normal breast and breast tumor tissues: In vivo and in vitro studies
83. Stimulation of aromatase P450 promoter (II) activity in endometriosis and its inhibition in endometrium are regulated by competitive binding of steroidogenic factor-1 and chicken ovalbumin upstream promoter transcription factor to the same cis-acting element
84. Analysis of the aromatase cytochrome P450 gene in human breast cancers
85. Breast cancer risk associated with polymorphism in CYP19 in Japanese women
86. Tetranucleotide repeat polymorphism at the human aromatase cytochrome p450 gene (CYP19)
87. Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk
88. Polymorphic variation in CYP19 and the risk of breast cancer
89. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk
90. A rare CYP19 (aromatase) variant may increase the risk of breast cancer
91. Genetic variants of CYP19 (aromatase) and breast cancer risk
92. CYP19 gene polymorphism in endometrial cancer patients
93. Thyroid disease in pregnancy. ACOG practice bulletin no. 32